Skip to content
Live funding
Sesame Summit 2027
Sesamers

Orakl Oncology raises $34M Series A to test cancer drugs on virtual patients

Paris-based Orakl Oncology raised a $34M Series A co-led by Norrsken VC and Singular to scale its AI platform that predicts cancer drug response from lab-grown patient tumors.

Microscope and petri dish on a laboratory bench

Also see more funding coverage: /funding/

Round at a glance
€30.8MSeries A Announced 13 November 2026
Founded 2023 · Paris, France
CompanyOrakl Oncology · profile
HQParis, France
StageSeries A
Participants HCVC InfraVia Growth Patient Autonome Fund Plug and Play Serena Speedinvest Teampact Ventures Verve Ventures Patient Autonome Fund (Bpifrance) Thomas Wolf Stan Polu Jacques Boitreaud Mostafa El Sayed

Paris-based Orakl Oncology has raised a $34M Series A, oversubscribed according to the release, co-led by Norrsken VC and Singular, to grow its AI platform, which predicts how cancer patients will respond to treatments using tumors grown in the lab from real patients.

A $34M Series A co-led by Norrsken VC and Singular

Orakl Oncology announced the round on 13 November 2026 in a press release datelined Paris. EU-Startups headlined it at about €30M, and our record converts the $34M to €30.8M at the xe.com mid-market rate of 15 November 2026 (1 EUR = 1.10229 USD).

Get the Weekly brief

The week’s rounds, last calls and events, every Monday.

Norrsken VC and Singular co-led. New investors are InfraVia Growth, Serena, the Patient Autonome Fund managed by Bpifrance, teampact.ventures and Plug and Play. Verve Ventures, Speedinvest and HCVC came back in, and four angels joined: Thomas Wolf, Stan Polu, Jacques Boitreaud and Mostafa El Sayed. Including this round, Orakl has raised $50M in total, according to the release.

The money is split across four areas. Research comes first, with new AI models, a broader dataset and a larger AI research team. Orakl also plans to increase data generation fivefold and to move beyond colorectal and pancreatic cancer into non-small cell lung cancer (NSCLC) and gastric cancer. On the commercial side, new teams in the US and the UK will deploy its predictions across more than 10 drug programs with pharma partners. The fourth area is target discovery, where Orakl wants to identify and validate new drug co-targets from patient biology and perturbational screens.

“We’re proud to continue backing the team as they scale,” said Jeremy Uzan, co-founder and general partner at Singular.

From a Gustave Roussy lab to more than 40 people in three years

Orakl was founded in 2023 as a spin-out of Gustave Roussy in Villejuif. Dr. Fanny Jaulin is CEO and co-founder, Dr. Gustave Ronteix is CTO and Dr. Diane-Laure Pagès is COO. According to the company, the team counts more than 40 people and 30% of them hold PhDs.

Orakl grows tumors in the lab from real patients and links each one to that patient’s medical history and biological data. Put together, those samples form cohorts of “virtual” cancer patients. Its AI platform uses them to predict how patients will respond to a treatment and how a clinical trial is likely to turn out. It also flags the patients most likely to respond and the mechanisms behind sensitivity and resistance. Candidate drug targets go back to the lab for validation, a loop the company calls “lab-in-the-loop”. Orakl reports 90% accuracy in prospective predictions. That figure comes from the company and has not been independently verified.

This is the third round in our records. A €3M seed, announced in early October 2023 and reported by BioSpace, was led by Speedinvest with HCVC and Verve Ventures. An €11M seed followed in December 2024, reported by Tech.eu on 3 December 2024.

The traction figures are the company’s own. Just over a year after its commercial launch, Orakl says 18 of the world’s 20 largest pharma companies are in its commercial pipeline, with early engagements turning into multiyear collaborations. It is negotiating with more than 15 additional cancer centers in Europe, North America and Asia. Philip Tagari, CSO of insitro after 24 years at Amgen, joins as an advisor.

“We believe the next breakthrough will come from making tumor and patient biology predictable,” said Jaulin.

A $6.93bn market and two neighbors in our November data

Precedence Research, in a press release dated 20 November 2025, sizes the global AI in drug discovery market at USD 6.93 billion in 2025 and forecasts USD 16.52 billion by 2034, a CAGR of 10.10% over 2025-2034. Estimates vary by publisher, and no European share is available in that release.

On 10 November, London-based Oyster Therapeutics raised a $60M Series A led by 4BIO Capital, with Eli Lilly joining. Two days later, Biomatter closed an $18M Series A led by Astanor for AI enzyme design. In euro terms our records put Biomatter at €16.3M and Oyster at €54.1M, each converted at the rate on its announcement date, with Orakl’s €30.8M sitting between them. That makes three life-science Series A rounds between 10 and 13 November.

Where a 75% Phase 2 failure rate meets lab-grown tumors

The release cites a BIO, Informa and QLS study that puts the failure rate of oncology candidates in Phase 2 at about 75%. Orakl positions its platform against that attrition. Agate Freimane, general partner at Norrsken VC, said Orakl “is tackling this bottleneck with a platform combining proprietary biological data”.

Orakl’s raw material is patient tumor samples from cancer centers. It came out of one and says it is negotiating with more than 15 others on three continents. The platform is meant to show a pharma team its likely responders, and the reasons others resist, before the first Phase 2 patient is enrolled. The move into lung and gastric cancer will show whether the approach travels beyond the two cancers it started with.

Orakl’s investor list mixes a Nordic-rooted lead, a fund managed by Bpifrance and four individual angels with returning investors Verve Ventures, Speedinvest and HCVC. Eli Lilly joined Oyster’s round as an investor, while Orakl says most of the top 20 pharma companies are in its commercial pipeline.

The 90% figure will get its real test in lung and gastric cancer, and in the drug programs the new US and UK teams take on. That is the figure to watch.

Get the weekly briefing Europe's rounds, founders & events - every Monday, in five minutes.